Optimal vaccination schedule search using genetic algorithm over MPI technology

BackgroundImmunological strategies that achieve the prevention of tumor growth are based on the presumption that the immune system, if triggered before tumor onset, could be able to defend from specific cancers. In supporting this assertion, in the last decade active immunization approaches prevented some virus-related cancers in humans. An immunopreventive cell vaccine for the non-virus-related human breast cancer has been recently developed. This vaccine, called Triplex, targets the HER-2-neu oncogene in HER-2/neu transgenic mice and has shown to almost completely prevent HER-2/neu-driven mammary carcinogenesis when administered with an intensive and life-long schedule.MethodsTo better understand the preventive efficacy of the Triplex vaccine in reduced schedules we employed a computational approach. The computer model developed allowed us to test in silico specific vaccination schedules in the quest for optimality. Specifically here we present a parallel genetic algorithm able to suggest optimal vaccination schedule.Results & ConclusionsThe enormous complexity of combinatorial space to be explored makes this approach the only possible one. The suggested schedule was then tested in vivo, giving good results. Finally, biologically relevant outcomes of optimization are presented.

[1]  P. Robbins,et al.  A listing of human tumor antigens recognized by T cells , 2001, Cancer Immunology, Immunotherapy.

[2]  Francesco Pappalardo,et al.  SimB16: Modeling Induced Immune System Response against B16-Melanoma , 2011, PloS one.

[3]  Francesco Pappalardo,et al.  Optimal vaccination schedules using simulated annealing , 2008, Bioinform..

[4]  Kalyanmoy Deb,et al.  A Comparative Analysis of Selection Schemes Used in Genetic Algorithms , 1990, FOGA.

[5]  Massimo Bernaschi,et al.  ImmunoGrid, an integrative environment for large-scale simulation of the immune system for vaccine discovery, design and optimization , 2008, Briefings Bioinform..

[6]  G. Parmiani,et al.  A listing of human tumor antigens recognized by T cells: March 2004 update , 2005, Cancer Immunology, Immunotherapy.

[7]  Francesco Pappalardo,et al.  MODELING TUMOR IMMUNOLOGY , 2006 .

[8]  Federica Cavallo,et al.  Vaccines for tumour prevention , 2006, Nature Reviews Cancer.

[9]  C. Bianca,et al.  Immune System Network and Cancer Vaccine , 2011 .

[10]  Massimo Bernaschi,et al.  ImmunoGrid: towards agent-based simulations of the human immune system at a natural scale† , 2010, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[11]  Piero Musiani,et al.  Immunoprevention of HER-2/neu Transgenic Mammary Carcinoma through an Interleukin 12-Engineered Allogeneic Cell Vaccine , 2004, Cancer Research.

[12]  Melanie Mitchell,et al.  An introduction to genetic algorithms , 1996 .

[13]  Vladimir Brusic,et al.  Combining cellular automata and Lattice Boltzmann method to model multiscale avascular tumor growth coupled with nutrient diffusion and immune competition. , 2012, Journal of immunological methods.

[14]  F. Pappalardo,et al.  In silico modeling and in vivo efficacy of cancer-preventive vaccinations. , 2010, Cancer research.

[15]  R. Schreiber,et al.  The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.

[16]  Robert D. Cardiff,et al.  Insights from transgenic mouse models of ERBB2-induced breast cancer , 2007, Nature Reviews Cancer.

[17]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[18]  Federica Cavallo,et al.  Vaccines and other immunological approaches for cancer immunoprevention. , 2011, Current drug targets.

[19]  A. Abbas,et al.  Cellular and Molecular Immunology , 1991 .

[20]  Riccardo Poli,et al.  New ideas in optimization , 1999 .

[21]  Filippo Castiglione,et al.  A Modeling Framework For Immune-related Diseases , 2012 .

[22]  P. Musiani,et al.  Antimetastatic activity of a preventive cancer vaccine. , 2007, Cancer research.

[23]  C. Bianca,et al.  The triplex vaccine effects in mammary carcinoma: A nonlinear model in tune with SimTriplex ☆ , 2012 .

[24]  Filippo Castiglione,et al.  Mathematical and Computational Models in Tumor Immunology , 2012 .

[25]  Filippo Castiglione,et al.  Vaccine protocols optimization: in silico experiences. , 2010, Biotechnology advances.

[26]  Zvia Agur Biomathematics in the development of personalized medicine in oncology. , 2006, Future oncology.

[27]  Federica Cavallo,et al.  2011: the immune hallmarks of cancer , 2011, Cancer Immunology, Immunotherapy.

[28]  C. Melief,et al.  Cancer immunology. , 2011, Current opinion in immunology.

[29]  Filippo Castiglione,et al.  Modeling and simulation of cancer immunoprevention vaccine , 2005, Bioinform..

[30]  Piero Musiani,et al.  Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice , 2001, The Journal of experimental medicine.

[31]  Francesco Pappalardo,et al.  Modeling the competition between lung metastases and the immune system using agents , 2010, BMC Bioinformatics.